Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2020-09-09 Earnings Release
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces "CARMAT reports its 2020 half-year results and issues an update on its activities and outlook." It contains summarized financial tables for the six months ended June 30, 2020, and discusses clinical trial progress and future outlook. This structure—a press release format summarizing period-specific financial performance (half-year) without being the full, detailed regulatory filing—aligns perfectly with the definition of an Earnings Release (ER). Although it contains detailed financial commentary, the primary format is a press release announcing results, not the comprehensive Interim/Quarterly Report (IR) itself, nor is it a transcript (CT) or a full Annual Report (10-K). The footnote mentions the '2020 half-year financial report was published today,' suggesting this document is the preliminary announcement, making ER the most appropriate classification. H1 2020
2020-09-09 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2020' (Semi-Annual Financial Report 2020) and covers the period ending June 30, 2020. It contains detailed financial statements (balance sheet, income statement), management's discussion and analysis (activity report, financial structure, COVID-19 impact), and a declaration by the responsible person. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H2 2020
2020-09-09 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "CARMAT publie ses résultats semestriels 2020 et fait le point sur ses activités et perspectives" (CARMAT publishes its 2020 half-year results and provides an update on its activities and outlook). It explicitly details the "Résultats semestriels 2020" (Half-year 2020 results) including a simplified income statement for the 6 months ended June 30, 2020, and discusses financial structure and clinical progress for the first half of the year. This content strongly indicates a comprehensive report covering a period shorter than a year. The footnote confirms that the "rapport financier semestriel 2020 a été publié ce jour" (the 2020 half-year financial report was published today). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is presented as a press release, the core content is the detailed financial report for the interim period. H1 2020
2020-09-09 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal declaration dated September 2, 2020, providing an update on the total number of voting rights and shares comprising the capital of the company, as required by Article 223-16 of the General Regulation of the Autorité des marchés financiers (AMF). This type of filing, which reports changes in share capital structure and voting rights, aligns most closely with notifications regarding share capital changes or major shareholdings. Since it explicitly details the 'Nombre total de droits de vote et d'actions composant le capital social' (Total number of voting rights and shares comprising the capital), it fits the description of a capital structure update. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a formal declaration detailing the total share count and voting rights, as this directly relates to the capital structure.
2020-09-02 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces the publication of study results in a medical journal ('Journal of Heart and Lung Transplantation'). It details clinical trial outcomes (PIVOTAL study) and includes quotes from the CEO and lead surgeon. This format—a brief announcement highlighting key achievements and referencing external validation (the journal publication)—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR) or a presentation (IP), and it is focused on communicating recent operational/clinical success rather than just announcing a future report release (RPA), the best fit among the provided options is Earnings Release (ER), as clinical trial milestones often accompany or substitute for traditional quarterly financial updates in biotech/medtech, or it could be classified as a Regulatory Filing (RNS) if it doesn't fit ER. Given the structure and purpose (announcing positive news/milestones), ER is a strong candidate, but since it is purely clinical/scientific news, RNS (General Regulatory/Miscellaneous Announcement) is often used for such specific, non-financial press releases. However, looking at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical highlight. If we consider this a significant operational update, ER is plausible. If we treat it as a general corporate announcement not fitting other specific categories, RNS applies. Given the high-profile nature of the publication announcement, and the lack of explicit financial figures (revenue, profit, etc.), RNS is the safer, broader classification for a scientific press release that doesn't fit the core financial reports or specific operational updates like M&A or Capital changes. I will lean towards RNS as the most appropriate fallback for a scientific press release.
2020-08-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the publication of clinical trial results in a medical journal ("Journal of Heart and Lung Transplantation"). It details the findings of the PIVOT study regarding the CARMAT artificial heart used as a bridge to transplantation. This type of announcement, which communicates significant operational or clinical news via a press release format, typically falls under a general regulatory announcement or a specific category if one fits better. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is not soliciting votes (DEF 14A/PSI), the most appropriate classification is a general Regulatory Filing (RNS), as it is a formal, non-financial regulatory communication. However, given the content is a major announcement about clinical data and study outcomes, it could also be considered an Investor Presentation (IP) if it were a slide deck, or perhaps a Legal/Regulatory update (LTR) if the publication itself was a regulatory requirement. Since it is a press release announcing a publication, and RNS is the fallback for general regulatory announcements, RNS is the best fit among the provided options for a non-financial, non-earnings related corporate update. Revisiting the definitions: It is not an ER, IR, 10-K, or MDA. It is not about management changes (MANG) or director trades (DIRS). It is a communication of scientific/clinical progress. RNS serves as the catch-all for regulatory announcements that don't fit elsewhere. This fits that description well.
2020-08-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.